Alivus Life Sciences Q2 FY27 earnings call on Oct 30, 2026

Board & Shareholder Meetings View source PDF Explain this filing

ALIVUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.2%Reaction day

₹1271.00

prior close

₹1277.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.3%+0.1% vs market

Pharmaceuticals peers, median of 170sector-1.5%-0.7% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.5

10m

-2.3

15m

-2.6

30m

-3.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.2-2.3+0.1-1.5-0.7

Next day

-0.8-1.9+1.1-0.4-0.4

+6.8pendingpending+1.5+5.3

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alivus Life Sciences (formerly Glenmark Life Sciences, BSE: 543322) has announced its Q2 FY2026-27 earnings call scheduled for Friday, October 30, 2026, from 8:30 am to 9:30 am IST. The company is inviting investors and analysts to join the call, with dial-in numbers provided for India and international participants, plus an online pre-registration link. Investor relations is handled by EY, with Diwakar Pingle and Runjhun Jain as contact points.

Likely market impact

Investors can expect Q2 FY27 results commentary; near-term stock movement may follow post-call management guidance.